Top

Published in:

01-06-2018 | Original Research Article

Prescription of Zolpidem and the Risk of Fatal Motor Vehicle Collisions: A Population-Based, Case-Crossover Study from South Korea

Authors: Bo Ram Yang, Ye-Jee Kim, Mi-Sook Kim, Sun-Young Jung, Nam-Kyong Choi, Byungkwan Hwang, Byung-Joo Park, Joongyub Lee

Published in: CNS Drugs | Issue 6/2018

Abstract

Background

Zolpidem is one of the most frequently used hypnotics worldwide, but associations with serious adverse effects such as motor vehicle collisions have been reported.

Objective

The objective of this study was to evaluate the association of fatal motor vehicle collisions with a prescription for zolpidem, considering the context of the motor vehicle collisions.

Methods

We conducted a case-crossover study, where each case served as its own control, by linking data about fatal motor vehicle collisions from the Korean Road Traffic Authority between 2010 and 2014 with national health insurance data. The case period was defined as 1 day before the fatal motor vehicle collisions, and was matched to four control periods at 90-day intervals. Conditional logistic regression was performed to calculate the odds ratio for fatal motor vehicle collisions associated with zolpidem exposure, and odds ratios were adjusted for time-varying exposure to confounding medications. A stratified analysis was performed by age group (younger than 65 years or not), the Charlson Comorbidity Index, and whether patients were new zolpidem users.

Results

Among the 714 subjects, the adjusted odds ratio for a fatal motor vehicle collision associated with a prescription for zolpidem the previous day was 1.48 (95% confidence interval 1.06–2.07). After stratification, a significantly increased risk was observed in subjects with a high Charlson Comorbidity Index (odds ratio 1.81; 95% confidence interval 1.16–2.84), the younger age group (odds ratio: 1.62; 95% confidence interval 1.03–2.56), and new zolpidem users (odds ratio 2.37; 95% confidence interval 1.40–4.00).

Conclusion

A prescription for zolpidem on the previous day was significantly related to an increased risk of fatal motor vehicle collisions in this population-based case-crossover study.

Pallesen S, Sivertsen B, Nordhus IH, Bjorvatn B. A 10-year trend of insomnia prevalence in the adult Norwegian population. Sleep Med. 2014;15(2):173–9.CrossRefPubMed

Calem M, Bisla J, Begum A, Dewey M, Bebbington PE, Brugha T, et al. Increased prevalence of insomnia and changes in hypnotics use in England over 15 years: analysis of the 1993, 2000, and 2007 National Psychiatric Morbidity Surveys. Sleep. 2012;35(3):377–84.CrossRefPubMedPubMedCentral

Chung S, Park B, Yi K, Lee J. Pattern of hypnotic drug prescription in South Korea: health insurance review and assessment service: national patients sample. Sleep Med Res. 2013;4(2):51–5.CrossRef

Gunja N. In the Zzz zone: the effects of Z-drugs on human performance and driving. J Med Toxicol. 2013;9(2):163–71.CrossRefPubMedPubMedCentral

Gunja N. The clinical and forensic toxicology of Z-drugs. J Med Toxicol. 2013;9(2):155–62.CrossRefPubMedPubMedCentral

Berthelon C, Bocca ML, Denise P, Pottier A. Do zopiclone, zolpidem and flunitrazepam have residual effects on simulated task of collision anticipation? J Psychopharmacol. 2003;17(3):324–31.CrossRefPubMed

Ganzoni E, Santoni JP, Chevillard V, Sebille M, Mathy B. Zolpidem in insomnia: a 3-year post-marketing surveillance study in Switzerland. J Int Med Res. 1995;23(1):61–73.CrossRefPubMed

Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297–328.CrossRefPubMed

Gibson JE, Hubbard RB, Smith CJ, Tata LJ, Britton JR, Fogarty AW. Use of self-controlled analytical techniques to assess the association between use of prescription medications and the risk of motor vehicle crashes. Am J Epidemiol. 2009;169(6):761–8.CrossRefPubMed

10.

Gustavsen I, Bramness JG, Skurtveit S, Engeland A, Neutel I, Morland J. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. Sleep Med. 2008;9(8):818–22.CrossRefPubMed

11.

Orriols L, Philip P, Moore N, Castot A, Gadegbeku B, Delorme B, et al. Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther. 2011;89(4):595–601.CrossRefPubMed

12.

Yang YH, Lai JN, Lee CH, Wang JD, Chen PC. Increased risk of hospitalization related to motor vehicle accidents among people taking zolpidem: a case-crossover study. J Epidemiol. 2011;21(1):37–43.CrossRefPubMedPubMedCentral

13.

Jung SY, Hwang B, Yang BR, Kim YJ, Lee J. Risk of motor vehicle collisions associated with medical conditions and medications: rationale and study protocol. Inj Prev. 2017;23(5):356.CrossRefPubMed

14.

Cheol Seong S, Kim YY, Khang YH, Heon Park J, Kang HJ, Lee H, et al. Data resource profile: the national health information database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2017;46(3):799–800.PubMed

15.

Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. 1991;133(2):144–53.CrossRefPubMed

16.

Food Korea, Administration Drug. Appropriate prescribing guideline for the elderly. Seoul: Korea Food and Drug Administration; 2009.

17.

Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.CrossRefPubMed

18.

Bannay A, Chaignot C, Blotiere PO, Basson M, Weill A, Ricordeau P, et al. The best use of the Charlson Comorbidity Index with electronic health care database to predict mortality. Med Care. 2016;54(2):188–94.CrossRefPubMed

19.

Huang YQ, Gou R, Diao YS, Yin QH, Fan WX, Liang YP, et al. Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy. J Zhejiang Univ Sci B. 2014;15(1):58–66.CrossRefPubMedPubMedCentral

20.

Robertson MD, Drummer OH. Responsibility analysis: a methodology to study the effects of drugs in driving. Accid Anal Prev. 1994;26(2):243–7.CrossRefPubMed

21.

Cheng HT, Lin FJ, Erickson SR, Hong JL, Wu CH. The association between the use of zolpidem and the risk of Alzheimer’s disease among older people. J Am Geriatr Soc. 2017;65(11):2488–95.CrossRefPubMed

22.

Breslow NE, Day NE. Statistical methods in cancer research. Volume I. The analysis of case-control studies. IARC Sci Publ. 1980;32:5–338.

23.

Firth D. Bias reduction of maximum-likelihood-estimates. Biometrika. 1993;80(1):27–38.CrossRef

24.

Sun JX, Sinha S, Wang SJ, Maiti T. Bias reduction in conditional logistic regression. Stat Med. 2011;30(4):348–55.CrossRefPubMed

25.

Booth JN, Behring M, Cantor RS, Colantonio LD, Davidson S, Donnelly JP, et al. Zolpidem use and motor vehicle collisions in older drivers. Sleep Med. 2016;20:98–102.CrossRefPubMed

26.

Meskali M, Berthelon C, Marie S, Denise P, Bocca ML. Residual effects of hypnotic drugs in aging drivers submitted to simulated accident scenarios: an exploratory study. Psychopharmacology (Berl). 2009;207(3):461–7.CrossRef

27.

Verster JC, Volkerts ER, Schreuder AH, Eijken EJ, van Heuckelum JH, Veldhuijzen DS, et al. Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. J Clin Psychopharmacol. 2002;22(6):576–83.CrossRefPubMed

28.

Vermeeren A, Ohanlon JF, Declerck AC, Kho L. Acute effects of zolpidem and flunitrazepam on sleep, memory and driving performance, compared to those of partial sleep-deprivation and placebo. Acta Therap. 1995;21(1):47–64.

29.

Verster JC, Volkerts ER, Olivier B, Johnson W, Liddicoat L. Zolpidem and traffic safety: the importance of treatment compliance. Curr Drug Saf. 2007;2(3):220–6.CrossRefPubMed

30.

Wong CK, Marshall NS, Grunstein RR, Ho SS, Fois RA, Hibbs DE, et al. Spontaneous adverse event reports associated with zolpidem in the United States 2003–2012. J Clin Sleep Med. 2017;13(2):223–34.CrossRefPubMedPubMedCentral

31.

Paulke A, Wunder C, Toennes SW. Sleep self-intoxication and sleep driving as rare zolpidem-induced complex behaviour. Int J Legal Med. 2015;129(1):85–8.CrossRefPubMed

32.

Hoque R, Chesson AL Jr. Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. J Clin Sleep Med. 2009;5(5):471–6.PubMedPubMedCentral

33.

Poceta JS. Zolpidem ingestion, automatisms, and sleep driving: a clinical and legal case series. J Clin Sleep Med. 2011;7(6):632–8.PubMedPubMedCentral

34.

Mortaz Hejri S, Faizi M, Babaeian M. Zolpidem-induced suicide attempt: a case report. DARU. 2013;21(1):77.CrossRefPubMedPubMedCentral

35.

Sun Y, Lin CC, Lu CJ, Hsu CY, Kao CH. Association between zolpidem and suicide: a nationwide population-based case-control study. Mayo Clin Proc. 2016;91(3):308–15.CrossRefPubMed

36.

Nevriana A, Moller J, Laflamme L, Monarrez-Espino J. New, occasional, and frequent use of zolpidem or zopiclone (alone and in combination) and the risk of injurious road traffic crashes in older adult drivers: a population-based case-control and case-crossover study. CNS Drugs. 2017;31(8):711–22.CrossRefPubMedPubMedCentral

37.

Booth JN 3rd, Behring M, Cantor RS, Colantonio LD, Davidson S, Donnelly JP, et al. Zolpidem use and motor vehicle collisions in older drivers. Sleep Med. 2016;20:98–102.CrossRefPubMed

38.

Fong CK, Keay L, Coxon K, Clarke E, Brown J. Seat belt use and fit among drivers aged 75 years and older in their own vehicles. Traffic Inj Prev. 2016;17(2):142–50.CrossRefPubMed

39.

Gwyther H, Holland C. The effect of age, gender and attitudes on self-regulation in driving. Accid Anal Prev. 2012;45:19–28.CrossRefPubMed

40.

Zint K, Haefeli WE, Glynn RJ, Mogun H, Avorn J, Sturmer T. Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol Drug Saf. 2010;19(12):1248–55.CrossRefPubMedPubMedCentral

41.

Vlase L, Popa A, Neag M, Muntean D, Achim M, Leucuta SE. Effect of fluvoxamine on the pharmokinetics of zolpidem: a two-treatment period study in healthy volunteers. Clin Exp Pharmacol Physiol. 2012;39(1):9–12.CrossRefPubMed

42.

Coleman DE, Ota K. Hallucinations with zolpidem and fluoxetine in an impaired driver. J Forensic Sci. 2004;49(2):392–3.CrossRefPubMed

Title: Prescription of Zolpidem and the Risk of Fatal Motor Vehicle Collisions: A Population-Based, Case-Crossover Study from South Korea
Authors: Bo Ram Yang
Ye-Jee Kim
Mi-Sook Kim
Sun-Young Jung
Nam-Kyong Choi
Byungkwan Hwang
Byung-Joo Park
Joongyub Lee
Publication date: 01-06-2018
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 6/2018
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.1007/s40263-018-0520-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prescription of Zolpidem and the Risk of Fatal Motor Vehicle Collisions: A Population-Based, Case-Crossover Study from South Korea

Abstract

Background

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2018

Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview

Tailoring Treatment in Polymorbid Migraine Patients through Personalized Medicine

Correction to: Gadolinium-Based Contrast Agent-Related Toxicities

A Systematic Review and Meta-Analysis of the Risk of Dementia Associated with Benzodiazepine Use, After Controlling for Protopathic Bias

Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer’s Disease

Polypharmacy Among Headache Patients: A Cross-Sectional Study